Shandong Buchang Pharmaceuticals' (SHA:603858) unit, Baoding Tianhao Pharmaceutical, received the drug registration certificate for oseltamivir phosphate dry suspension from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Friday.
The certificate will allow the manufacturing and sales of the drug, which is used for the treatment of patients with influenza A and B.
The pharmaceutical company invested 14.4 million yuan into the research and development of the drug.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。